What's Happening?
Researchers at KAIST have developed an RNA-based therapeutic strategy to combat cancer cachexia, a condition that causes severe weight and muscle loss in cancer patients. The therapy targets the GFRAL receptor in the brainstem, which is activated by the protein
GDF15 secreted by cancer cells. By using antisense oligonucleotides to block GFRAL production, the treatment prevents the cachexia-inducing signal, reducing muscle and fat loss and improving metabolic function in mice. The study, published in Cell Reports Medicine, demonstrates significant survival benefits in treated mice.
Why It's Important?
Cancer cachexia affects a large percentage of cancer patients, leading to physical decline and reduced effectiveness of treatments. Current therapies only temporarily boost appetite without addressing the underlying causes of muscle loss. This new approach targets the root cause of cachexia, offering a potential breakthrough in improving patient quality of life and treatment outcomes. By focusing on the brain's role in cachexia, the therapy could complement existing cancer treatments and enhance survival rates.
What's Next?
The research team plans to advance preclinical studies and develop the therapy for clinical use by 2030. Further research will focus on optimizing the treatment for human application and exploring its potential as an adjuvant therapy alongside existing cancer treatments. The goal is to improve patient outcomes by addressing both cancer progression and cachexia, ultimately enhancing the effectiveness of cancer therapies.
